Related references
Note: Only part of the references are listed.Combination Therapies in Chronic Myeloid Leukemia for Potential Treatment-Free Remission: Focus on Leukemia Stem Cells and Immune Modulation
Hui Mu et al.
FRONTIERS IN ONCOLOGY (2021)
Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study
Neil P. Shah et al.
LEUKEMIA & LYMPHOMA (2020)
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
A. Hochhaus et al.
LEUKEMIA (2020)
Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring
Elias Jabbour et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Increased tumor burden in patients with chronic myeloid leukemia after 36 months of imatinib discontinuation
Elisa Diral et al.
BLOOD (2020)
Chronic Myeloid Leukemia, Version 2.2021
Michael W. Deininger et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2020)
De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial
Richard E. Clark et al.
LANCET HAEMATOLOGY (2019)
Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience
Kamal Chamoun et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase
Francois-Xavier Mahon et al.
ANNALS OF INTERNAL MEDICINE (2018)
Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: Recommendations for Clinical Practice From the French Chronic Myeloid Leukemia Study Group
Delphine Rea et al.
CANCER (2018)
Final 3-year Results of the Dasatinib Discontinuation Trial in Patients With Chronic Myeloid Leukemia Who Received Dasatinib as a Second-line Treatment
Masaya Okada et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2018)
Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial
Susanne Saussele et al.
LANCET ONCOLOGY (2018)
Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study
Delphine Rea et al.
BLOOD (2017)
Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia
Gabriel Etienne et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study
Sung-Eun Lee et al.
HAEMATOLOGICA (2016)
Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study
Sung-Eun Lee et al.
HAEMATOLOGICA (2016)
Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable Disease
Philippe Rousselot et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
David M. Ross et al.
BLOOD (2013)
Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia
Naoto Takahashi et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Relapse and Late Mortality in 5-Year Survivors of Myeloablative Allogeneic Hematopoietic Cell Transplantation for Chronic Myeloid Leukemia in First Chronic Phase
John M. Goldman et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
Francois-Xavier Mahon et al.
LANCET ONCOLOGY (2010)
Share Paper
